• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Bagger Dave's Burger Tavern Inc
Bridgeline Digital, Inc. - Common Stock
Capstone Holding Corp. - Common Stock
Computershare Ltd AUD
Elite Pharms Inc
Global Energy Metals Corp
Growlife Inc
Mexco Energy Corporation Common Stock
Mongolian Mining Corp
NewtekOne, Inc. - Depositary Shares
Organto Foods Inc
Panasonic Hldgs Corp ADR
Porter & Company Porter Portfolio Index ETF
Porter & Company Property & Casualty Index ETF
Prairie Operating Co. - Common Stock
Robogroup T.E.K. Ltd
SciPlay Corporation - Class A Common Stock
Scorpius Holdings, Inc. Common Stock
Seaport Entertainment Group Inc. Common Stock
Standard Motor Products, Inc. Common Stock
Tate & Lyle Plc
TransAct Technologies Incorporated - Common Stock
Trio Petroleum Corp. Common Stock
Vanguard Industrials ETF
Vox Royalty Corp
Vuzix Corporation - Common Stock
Wartsila Corp
iShares Morningstar Small-Cap Growth ETF
iShares iBonds Dec 2022 Term Treasury ETF
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Appili Therapeutics Inc (OP:APLIF)

0.0068 +0.0013 (+23.64%)
Delayed Quote Updated: 12:40 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Appili Therapeutics Inc

< Previous 1 2 3 Next >
News headline image
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
October 30, 2024
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board
October 29, 2024
Via Investor Brand Network
News headline image
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
October 29, 2024
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
October 28, 2024
Via Investor Brand Network
News headline image
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 28, 2024
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans
October 21, 2024
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
October 10, 2024
Via Investor Brand Network
News headline image
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
October 10, 2024
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
October 08, 2024
Via Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
October 08, 2024
Via Investor Brand Network
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
October 03, 2024
Via Investor Brand Network
News headline image
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 03, 2024
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Via Investor Brand Network
News headline image
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 29, 2024
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
August 21, 2024
Via Investor Brand Network
News headline image
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 21, 2024
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
July 25, 2024
Via Investor Brand Network
News headline image
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
April 02, 2024
From Aditxt, Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
December 15, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
November 13, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
October 25, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
September 27, 2023
From Appili Therapeutics
Via Business Wire
News headline image
Appili Therapeutics Presents at the 10th International Tularemia Conference
September 27, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
September 25, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
August 11, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics – Press Release Correction
June 23, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
June 23, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
May 24, 2023
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023
From Appili Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap